Schmidt et al. 2 year results of SELECT-GCA, upadacitinib in GCA. Remission 69% if upa continued vs 29% if stopped. 90% lower risk of flare, 1G less steroid @RheumNow #ACR25 Abstr#0776 #ACRBest https://t.co/MgRo7kIgIw